Further to Azure Health Technology Limited's (
VTL's CEO and Managing Director, Dr Glenn Tong, said that this is a major milestone for VTL as we are now commencing the launch of both our patented nutraceutical products, NE1-Elite(R) for reduction of Delayed Onsent Muscle Soreness (DOMS) and NE1-Heart(R) for maintenance of heart health in the US.
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
Contact
Glenn TongCEO and Managing Director
Ph: +61 (0) 412 193 350
Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431
Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200
Related Companies
Related Industry Topics: